{"transactions":[{"id":1381988,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-24T20:15:07.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":false,"shares":391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":7682,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":391},"source":{"system":"sec-edgar","filing":"0001415889-24-025601","document":"form4-10242024_041001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025601/form4-10242024_041001.xml","form_type":"4"}},{"id":1381987,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-24T20:15:07.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":false,"shares":778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":11308,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":778},"source":{"system":"sec-edgar","filing":"0001415889-24-025601","document":"form4-10242024_041001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025601/form4-10242024_041001.xml","form_type":"4"}},{"id":1381986,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-24T20:15:07.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":false,"shares":778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":11308,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":778},"source":{"system":"sec-edgar","filing":"0001415889-24-025601","document":"form4-10242024_041001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025601/form4-10242024_041001.xml","form_type":"4"}},{"id":1381985,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-24T20:15:07.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":false,"shares":1868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":27138,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":1868},"source":{"system":"sec-edgar","filing":"0001415889-24-025601","document":"form4-10242024_041001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025601/form4-10242024_041001.xml","form_type":"4"}},{"id":1381984,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-24T20:15:07.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":3815,"price":46.68,"value":178084.2,"ownership":{"direct":true},"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001415889-24-025601","document":"form4-10242024_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025601/form4-10242024_041001.xml","form_type":"4"}},{"id":1381983,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-24T20:15:07.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":true,"shares":391,"price":39.8,"value":15561.8,"ownership":{"direct":true},"balance_after":10815,"source":{"system":"sec-edgar","filing":"0001415889-24-025601","document":"form4-10242024_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025601/form4-10242024_041001.xml","form_type":"4"}},{"id":1381982,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-24T20:15:07.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":true,"shares":778,"price":13.22,"value":10285.16,"ownership":{"direct":true},"balance_after":10424,"source":{"system":"sec-edgar","filing":"0001415889-24-025601","document":"form4-10242024_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025601/form4-10242024_041001.xml","form_type":"4"}},{"id":1381981,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-24T20:15:07.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":true,"shares":778,"price":10.73,"value":8347.94,"ownership":{"direct":true},"balance_after":9646,"source":{"system":"sec-edgar","filing":"0001415889-24-025601","document":"form4-10242024_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025601/form4-10242024_041001.xml","form_type":"4"}},{"id":1381980,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-24T20:15:07.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":true,"shares":1868,"price":17,"value":31756.0,"ownership":{"direct":true},"balance_after":8868,"source":{"system":"sec-edgar","filing":"0001415889-24-025601","document":"form4-10242024_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025601/form4-10242024_041001.xml","form_type":"4"}},{"id":1384172,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":false,"shares":237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6072,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":237},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384171,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":false,"shares":348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9142,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":348},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384170,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":false,"shares":348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9142,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":348},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384169,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":false,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":21940,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":836},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384168,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":false,"shares":1407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6309,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":1407},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384167,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":false,"shares":2070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9490,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":2070},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384166,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":false,"shares":2070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9490,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":2070},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384165,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":false,"shares":4968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":22776,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":4968},"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384164,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":553219,"price":44.75,"value":24756550.25,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2115373,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384163,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":104957,"price":44.75,"value":4696825.75,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":401321,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384162,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":541824,"price":44.75,"value":24246624.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2071799,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384161,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":15788,"price":51.18,"value":808029.84,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2668592,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384160,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":2995,"price":51.18,"value":153284.1,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":506278,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384159,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":15462,"price":51.18,"value":791345.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2613623,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384158,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":104892,"price":50.3,"value":5276067.6,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2684380,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384157,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":19900,"price":50.3,"value":1000970.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":509273,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384156,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":102732,"price":50.3,"value":5167419.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2629085,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384155,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"sale","planned":false,"acquired":false,"shares":1843,"price":50.02,"value":92186.86,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.97 to $50.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6371,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384154,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":true,"shares":237,"price":39.8,"value":9432.6,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8214,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384153,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":true,"shares":348,"price":13.22,"value":4600.56,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7977,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384152,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":true,"shares":348,"price":10.73,"value":3734.04,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7629,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384151,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-17","kind":"exercise","planned":false,"acquired":true,"shares":836,"price":17,"value":14212.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7281,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384150,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":10957,"price":50.8,"value":556615.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.76 to $51.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6445,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384149,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":true,"shares":1407,"price":39.8,"value":55998.6,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":17402,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384148,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":true,"shares":2070,"price":13.22,"value":27365.4,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":15995,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384147,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":true,"shares":2070,"price":10.73,"value":22211.1,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":13925,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384146,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"exercise","planned":false,"acquired":true,"shares":4968,"price":17,"value":84456.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11855,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384145,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":30094,"price":50.61,"value":1523057.34,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2789272,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384144,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":5710,"price":50.61,"value":288983.1,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":529173,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384143,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":29474,"price":50.61,"value":1491679.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2731817,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384142,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":61445,"price":49.69,"value":3053202.05,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2819366,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384141,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":11657,"price":49.69,"value":579236.33,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":534883,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1384140,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T22:51:26.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":60179,"price":49.69,"value":2990294.51,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2761291,"source":{"system":"sec-edgar","filing":"0001415889-24-025436","document":"form4-10182024_101021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924025436/form4-10182024_101021.xml","form_type":"4"}},{"id":1397946,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7716,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":123},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397945,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11560,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397944,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11560,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397943,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":434,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":27744,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":434},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397942,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7839,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":234},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397941,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11741,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":345},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397940,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":11741,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":345},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397939,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":28178,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":828},"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397938,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"sale","planned":false,"acquired":false,"shares":958,"price":46.24,"value":44297.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.24 to $46.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6887,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397937,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":123,"price":39.8,"value":4895.4,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7845,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397936,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":181,"price":13.22,"value":2392.82,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7722,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397935,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":181,"price":10.73,"value":1942.13,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7541,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397934,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":434,"price":17,"value":7378.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7360,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397933,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":1826,"price":46.19,"value":84342.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.11 to $46.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":6926,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397932,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":234,"price":39.8,"value":9313.2,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8752,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397931,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":345,"price":13.22,"value":4560.9,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8518,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397930,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":345,"price":10.73,"value":3701.85,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8173,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397929,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":828,"price":17,"value":14076.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7828,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397928,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":1542,"price":47.74,"value":73615.08,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2880811,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397927,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":293,"price":47.74,"value":13987.82,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":546540,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397926,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":1511,"price":47.74,"value":72135.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2821470,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397925,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":46861,"price":46.42,"value":2175287.62,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2882353,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397924,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":8894,"price":46.42,"value":412859.48,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":546833,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397923,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":45894,"price":46.42,"value":2130399.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2822981,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397922,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":41661,"price":47.77,"value":1990145.97,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2929214,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397921,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":7908,"price":47.77,"value":377765.16,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":555727,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397920,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":40803,"price":47.77,"value":1949159.31,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2868875,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397919,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":50539,"price":46.78,"value":2364214.42,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2970875,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397918,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":9592,"price":46.78,"value":448713.76,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":563635,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1397917,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T00:49:38.000Z","date":"2024-09-26","kind":"sale","planned":false,"acquired":false,"shares":49497,"price":46.78,"value":2315469.66,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2909678,"source":{"system":"sec-edgar","filing":"0001415889-24-024119","document":"form4-10012024_121033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924024119/form4-10012024_121033.xml","form_type":"4"}},{"id":1408742,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":161356,"price":47,"value":7583732.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3021414,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408741,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":30613,"price":47,"value":1438811.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":573227,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408740,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":158031,"price":47,"value":7427457.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":2959175,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408739,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":35047,"price":46.66,"value":1635293.02,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3182770,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408738,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":6649,"price":46.66,"value":310242.34,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":603840,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408737,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":34326,"price":46.66,"value":1601651.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3117206,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408736,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":11557,"price":46.13,"value":533124.41,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3217817,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408735,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":2193,"price":46.13,"value":101163.09,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":610489,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1408734,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-13T00:42:19.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":11319,"price":46.13,"value":522145.47,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3151532,"source":{"system":"sec-edgar","filing":"0001415889-24-023337","document":"form4-09132024_120915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023337/form4-09132024_120915.xml","form_type":"4"}},{"id":1410919,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8073,"derivative":{"exercise_price":39.8,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":277},"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410918,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":12086,"derivative":{"exercise_price":13.22,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":414},"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410917,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":12086,"derivative":{"exercise_price":10.73,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":414},"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410916,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":29006,"derivative":{"exercise_price":17,"expiration_date":"2027-07-19","underlying":"Common Stock","underlying_shares":994},"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410915,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":2182,"price":42.33,"value":92364.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.33 to $42.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410914,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":277,"price":39.8,"value":11024.6,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":9182,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410913,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":414,"price":13.22,"value":5473.08,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8905,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410912,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":414,"price":10.73,"value":4442.22,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8491,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410911,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":994,"price":17,"value":16898.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by Mr. Lichter."}],"balance_after":8077,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410910,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-06","kind":"sale","planned":false,"acquired":false,"shares":110644,"price":42,"value":4647048.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3229374,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410909,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-06","kind":"sale","planned":false,"acquired":false,"shares":20991,"price":42,"value":881622.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":612682,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1410908,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86694,"kind":"organization","name":"Avalon Ventures XI, L.P.","position":1,"cik":"0001652901","reported_name":"Avalon Ventures XI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86695,"kind":"organization","name":"Avalon BioVentures I, LP","position":2,"cik":"0001873935","reported_name":"Avalon BioVentures I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86696,"kind":"organization","name":"Avalon BioVentures SPV I, L.P.","position":3,"cik":"0001844550","reported_name":"Avalon BioVentures SPV I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":86607,"kind":"person","name":"Lichter Jay","position":4,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-10T21:02:56.000Z","date":"2024-09-06","kind":"sale","planned":false,"acquired":false,"shares":108365,"price":42,"value":4551330.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP, LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":3162851,"source":{"system":"sec-edgar","filing":"0001415889-24-023153","document":"form4-09102024_090952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924023153/form4-09102024_090952.xml","form_type":"4"}},{"id":1467314,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-28T20:30:51.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":8350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date."}],"balance_after":8350,"derivative":{"exercise_price":39.8,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":8350},"source":{"system":"sec-edgar","filing":"0001415889-24-018443","document":"form4-06282024_040646.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924018443/form4-06282024_040646.xml","form_type":"4"}},{"id":1467313,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-28T20:30:51.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date."}],"balance_after":7083,"source":{"system":"sec-edgar","filing":"0001415889-24-018443","document":"form4-06282024_040646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924018443/form4-06282024_040646.xml","form_type":"4"}},{"id":1490200,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T23:25:27.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":691525,"price":54.75,"value":37860993.75,"ownership":{"direct":false,"nature":"By Avalon BioVentures SPV I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly held by Avalon BioVentures SPV I, LP (\"ABV SPV\"). ABV SPV I GP LLC (\"ABV SPV GP\") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any."}],"balance_after":3340018,"source":{"system":"sec-edgar","filing":"0001415889-24-015678","document":"form4-06052024_110623.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924015678/form4-06052024_110623.xml","form_type":"4"}},{"id":1490199,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T23:25:27.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":131196,"price":54.75,"value":7182981.0,"ownership":{"direct":false,"nature":"By Avalon BioVentures I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by Avalon BioVentures I, LP (\"ABV I\"). Avalon BioVentures GP LLC (\"ABV GP\") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any."}],"balance_after":633673,"source":{"system":"sec-edgar","filing":"0001415889-24-015678","document":"form4-06052024_110623.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924015678/form4-06052024_110623.xml","form_type":"4"}},{"id":1490198,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T23:25:27.000Z","date":"2024-06-03","kind":"sale","planned":false,"acquired":false,"shares":677279,"price":54.75,"value":37081025.25,"ownership":{"direct":false,"nature":"By Avalon Ventures XI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Avalon Ventures XI, L.P. (\"Avalon Ventures\"). Avalon Ventures XI GP LLC (\"Avalon XI GP\") is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any."}],"balance_after":3271216,"source":{"system":"sec-edgar","filing":"0001415889-24-015678","document":"form4-06052024_110623.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000141588924015678/form4-06052024_110623.xml","form_type":"4"}},{"id":1740916,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-15T21:46:54.000Z","date":"2023-11-13","kind":"purchase","planned":false,"acquired":true,"shares":849854,"price":5.87,"value":4988642.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP LLC (ABV GP) is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. Dr. Lichter disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any."}],"balance_after":849854,"source":{"system":"sec-edgar","filing":"0001209191-23-055349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919123055349/doc4.xml","form_type":"4"}},{"id":1852517,"issuer":{"id":4864,"kind":"organization","name":"Janux Therapeutics, Inc."},"owners":[{"id":86607,"kind":"person","name":"Lichter Jay","position":1,"cik":"0001376355","reported_name":"Lichter Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:10:20.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders."}],"balance_after":12500,"derivative":{"exercise_price":13.22,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-23-037989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817713/000120919123037989/doc4.xml","form_type":"4"}}],"next_cursor":"2023-06-16T21:10:20.000000Z,1852517"}